315 related articles for article (PubMed ID: 20002781)
21. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
22. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
Potard V; Rey D; Mokhtari S; Frixon-Marin V; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
Antivir Ther; 2007; 12(3):317-24. PubMed ID: 17591021
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand.
Wilson D; Keiluhu AK; Kogrum S; Reid T; Seriratana N; Ford N; Kyawkyaw M; Talangsri P; Taochalee N
Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):601-6. PubMed ID: 19110288
[TBL] [Abstract][Full Text] [Related]
24. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
25. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
Phillips AN; Staszewski S; Lampe F; Youle MS; Klauke S; Bickel M; Sabin CA; Doerr HW; Johnson MA; Loveday C; Miller V; ;
J Infect Dis; 2002 Oct; 186(8):1086-91. PubMed ID: 12355358
[TBL] [Abstract][Full Text] [Related]
26. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
27. Successful simplification of HAART in patients with acute primary HIV infection.
Sinicco A; Bonora S; Arnaudo I; Zeme DA; Audagnotto S; Raiteri R; Di Perri G
J Biol Regul Homeost Agents; 2002; 16(1):69-72. PubMed ID: 12003178
[TBL] [Abstract][Full Text] [Related]
28. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
29. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
30. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
[TBL] [Abstract][Full Text] [Related]
31. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
[TBL] [Abstract][Full Text] [Related]
32. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting.
Ladak F; Socias E; Nolan S; Dong H; Kerr T; Wood E; Montaner J; Milloy MJ
Antivir Ther; 2019; 24(1):19-25. PubMed ID: 30230474
[TBL] [Abstract][Full Text] [Related]
33. Risk of high-level viraemia in HIV-infected patients on successful antiretroviral treatment for more than 6 months.
Engsig FN; Omland LH; Larsen MV; Rasmussen LD; Qvist T; Gerstoft J; Obel N
HIV Med; 2010 Aug; 11(7):457-61. PubMed ID: 20158527
[TBL] [Abstract][Full Text] [Related]
34. Measuring adherence to antiretroviral treatment: the role of pharmacy records of drug withdrawals.
Gutierrez EB; Sartori AM; Schmidt AL; Piloto BM; França BB; de Oliveira AS; Pouza AR; Moreno RV; de Melo Picone C; de Almeida Ribeiro MC
AIDS Behav; 2012 Aug; 16(6):1482-90. PubMed ID: 22392157
[TBL] [Abstract][Full Text] [Related]
35. Adherence to antiretroviral therapy in pediatric patients with human immunodeficiency virus (HIV-1).
Burack G; Gaur S; Marone R; Petrova A
J Pediatr Nurs; 2010 Dec; 25(6):500-4. PubMed ID: 21035017
[TBL] [Abstract][Full Text] [Related]
36. Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.
Navarro J; Pérez M; Curran A; Burgos J; Feijoo M; Torrella A; Caballero E; Ocaña I; Ribera E; Crespo M; Falcó V
AIDS Patient Care STDS; 2014 Oct; 28(10):537-42. PubMed ID: 25111167
[TBL] [Abstract][Full Text] [Related]
37. Linkage and retention in care and the time to HIV viral suppression and viral rebound - New York City.
Robertson M; Laraque F; Mavronicolas H; Braunstein S; Torian L
AIDS Care; 2015; 27(2):260-7. PubMed ID: 25244545
[TBL] [Abstract][Full Text] [Related]
38. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
[TBL] [Abstract][Full Text] [Related]
39. A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIV-infected children, adolescents, and young adults.
Kahana SY; Rohan J; Allison S; Frazier TW; Drotar D
AIDS Behav; 2013 Jan; 17(1):41-60. PubMed ID: 22411426
[TBL] [Abstract][Full Text] [Related]
40. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma.
Pasternak AO; de Bruin M; Jurriaans S; Bakker M; Berkhout B; Prins JM; Lukashov VV
J Infect Dis; 2012 Nov; 206(9):1443-52. PubMed ID: 22927449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
